Skip to main content
. Author manuscript; available in PMC: 2017 Jun 26.
Published in final edited form as: Mol Cancer Ther. 2010 Jul 6;9(7):2026–2036. doi: 10.1158/1535-7163.MCT-10-0238

Figure 6.

Figure 6

Antitumor effect(s) of degrasyn in combination with bortezomib in a MCL xeno-transplant SCID mouse model. (A) Schematic representation of the experimental protocol for the animal study described in Materials and Methods. Mice received a vehicle control (DMSO; group I), bortezomib alone (0.25 mg/kg; group II), degrasyn alone (20 mg/kg; group III), or bortezomib plus degrasyn (group IV). (B) Images of representative mice in each group at necropsy (day 65). The arrows indicate tumors. BZ, bortezomib. (C) Kaplan-Meier survival curve showing survival for mice treated with bortezomib, degrasyn, or bortezomib plus degrasyn at the indicated concentrations in the xeno-transplant SCID mouse model of MCL (n = 10). BZ, bortezomib. Bortezomib plus degrasyn-treated mice show significantly increased survival (P<0.0001) compared to the untreated control group. The mean overall survival (OS) was 79 days (95% confidence interval, CI; 65-90) in the untreated or single agent-treated cohorts versus 104 days (95% CI; 90-120) in the group treated with combination of bortezomib and degrasyn.